Dana B. Cardin - Concepedia

Author

Dana B. Cardin

Vanderbilt University ORCID

Also Known As

Christopher Andrews, D. B. Cardin, D. Cardin, Dana B Cardin, Dana B. Cardin, Dana Backlund Cardin, Dana Cardin

152

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

Vanderbilt University Vanderbilt University Medical Center Vanderbilt-Ingram Cancer Center The University of Texas MD Anderson Cancer Center The Barbara Ann Karmanos Cancer Institute

About

Dana B. Cardin is an author at Vanderbilt University specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	23	2.1K
2	Health Sciences	10	11	1.3K
3	Gastroenterology	3	3	1.4K
4	Cell Biology	1	1	18
5	Hepatology	1	1	20

Dana B. Cardin

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Margaret A. Tempero, Mokenge P. Malafa, Mahmoud M. Al-Hawary, Journal of the National Comprehensive Cancer Network	2021	1.2K
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology Margaret A. Tempero, Mokenge P. Malafa, Mahmoud M. Al-Hawary, Journal of the National Comprehensive Cancer Network Surgical OncologyOncologic ImagingGastroenterologyPathologySurgery	2017	1K
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Matthew H. G. Katz, Qian Shi, Syed A. Ahmad, JAMA Surgery	2016	443
Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019 Margaret A. Tempero, Mokenge P. Malafa, E. Gabriela Chiorean, Journal of the National Comprehensive Cancer Network Surgical OncologyPancreatic CancerGuidelines InsightsGastrointestinal OncologyMedicine	2019	365
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy Vincent Chung, Shannon McDonough, Philip A. Philip, JAMA Oncology	2016	173
Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Journal of Clinical Oncology	2022	120
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer S. Lindsey Davis, Dana B. Cardin, Safi Shahda, Investigational New Drugs Phase 1BPhase Ib StudyPancreatic CancerGastrointestinal OncologyMedicine	2019	99
Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) Heinz‐Josef Lenz, Eric Van Cutsem, María Luisa Limón, Annals of Oncology Low-dose IpilimumabMedicineImmunologyColorectal CancerPathology	2018	92
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors Elizabeth J. Davis, Juan Martín-Liberal, Rebecca Kristeleit, Journal for ImmunoTherapy of Cancer	2022	88
Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers Laura W. Goff, Nilay Thakkar, Liping Du, PLoS ONE	2014	86

Page 1